Literature DB >> 10702208

Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.

A Helmy1, R Jalan, D E Newby, P C Hayes, D J Webb.   

Abstract

BACKGROUND & AIMS: The renin-angiotensin and sympathetic nervous systems are activated in cirrhosis. This study aimed to establish the role of angiotensin II (ANG II) in the regulation of basal and sympathetically stimulated vascular tone in preascitic cirrhotic patients and patients with diuretic-refractory ascites compared with age- and sex-matched healthy controls.
METHODS: Forearm blood flow (FBF) responses to lower body negative pressure (LBNP) and to subsystemic, intrabrachial infusions of losartan, an angiotensin II type 1 (AT(1)) receptor antagonist, norepinephrine, and ANG II were measured using venous occlusion plethysmography.
RESULTS: In all groups, ANG II and norepinephrine caused dose-dependent reductions in FBF (P < 0.001); responses to norepinephrine were similar across the 3 groups but those to ANG II were less in both cirrhotic groups than in controls (P < 0.01). Losartan caused a dose-dependent increase in FBF only in patients with refractory ascites (P < 0.01). LBNP caused less reduction in FBF in refractory ascites patients than in both preascitic patients and controls (P < 0.01).
CONCLUSIONS: Despite hyporesponsiveness to exogenous ANG II in both early and advanced cirrhosis, endogenous ANG II contributes to the maintenance of basal vascular tone only in advanced cirrhosis. These findings suggest a role of ANG II in the pathogenesis of ascites. Attenuated LBNP responses occurred only in advanced cirrhosis, without apparent interaction with endogenous ANG II.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702208     DOI: 10.1016/s0016-5085(00)70263-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Does angiotensin II type 1 receptor blockade offer a clinical advantage to cirrhotics with ascites?

Authors:  Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

3.  Responses to endothelin-1 in patients with advanced cirrhosis before and after liver transplantation.

Authors:  A Helmy
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 4.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 5.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

6.  Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites.

Authors:  J W Ferguson; A R Dover; S Chia; N L M Cruden; P C Hayes; D E Newby
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

7.  Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation.

Authors:  R B Vaughan; P W Angus; J P F Chin-Dusting
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

9.  Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

Authors:  Walkíria Wingester Vilas-Boas; Antônio Ribeiro-Oliveira; Renata da Cunha Ribeiro; Renata Lúcia Pereira Vieira; Jerusa Almeida; Ana Paula Nadu; Ana Cristina Simões e Silva; Robson Augusto Souza Santos
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 10.  Overview on acute-on-chronic liver failure.

Authors:  Jing Zhang; Shan Gao; Zhongping Duan; Ke-Qin Hu
Journal:  Front Med       Date:  2016-03-14       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.